Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant

TerminatedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

April 22, 2019

Study Completion Date

April 22, 2019

Conditions
CMV
Interventions
DIAGNOSTIC_TEST

T-SPOT®.CMV Test

The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens. Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified. The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study. Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines. We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC. Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout. That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oxford Immunotec

INDUSTRY

lead

St. Jude Children's Research Hospital

OTHER